Last reviewed · How we verify
3% 2-chloroprocaine and epidural morphine
3% 2-chloroprocaine and epidural morphine, developed by The University of Texas Health Science Center, Houston, is a marketed drug with a key composition patent expiring in 2028. Its primary strength lies in its unique mechanism of action, which differentiates it from other anesthetics in the market. The primary risk is the lack of revenue data and key trial results, which may limit its commercial appeal and investor confidence.
At a glance
| Generic name | 3% 2-chloroprocaine and epidural morphine |
|---|---|
| Sponsor | The University of Texas Health Science Center, Houston |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Post-cesarean Analgesia With Epidural Morphine Following Epidural 2-chloroprocaine (PHASE4)
- Effect of Timing on Efficacy of Morphine Analgesia After 2-chloroprocaine Anesthesia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: